| 0.7 0.01 (1.45%) | 12-04 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 1.02 |
1-year : | 1.2 |
| Resists | First : | 0.87 |
Second : | 1.02 |
| Pivot price | 0.62 |
|||
| Supports | First : | 0.52 |
Second : | 0.3 |
| MAs | MA(5) : | 0.68 |
MA(20) : | 0.59 |
| MA(100) : | 0.66 |
MA(250) : | 0.95 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 80.7 |
D(3) : | 72.4 |
| RSI | RSI(14): 54.1 |
|||
| 52-week | High : | 4.73 | Low : | 0.25 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ VCNX ] has closed below upper band by 32.4%. Bollinger Bands are 8.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.69 - 0.69 | 0.69 - 0.69 |
| Low: | 0.3 - 0.3 | 0.3 - 0.3 |
| Close: | 0.66 - 0.67 | 0.67 - 0.68 |
Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs. The company offers its products for the treatment of cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab, a humanized monoclonal antibody that completed and planned Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), Huntington's disease, Alzheimer's disease, osteosarcoma, and melanoma. The company is also developing VX5, a human antibody to CXCL13 that is in preclinical development for the treatment of MS and for other autoimmune disorders. Vaccinex, Inc. was incorporated in 2001 and is headquartered in Rochester, New York.
Fri, 07 Mar 2025
Can Vaccinex Survive After Nasdaq Exit? Key Details on Company's Future Strategy - Stock Titan
Tue, 17 Dec 2024
Vaccinex, Inc. Faces Delisting from Nasdaq Due to Failure to Meet Continued Listing Standards - Nasdaq
Thu, 31 Oct 2024
Vaccinex reports progress in Alzheimer's treatment study - Investing.com
Mon, 12 Feb 2024
Steven Cohen's Point72 Asset Management Acquires New Stake in Vaccinex Inc - Yahoo Finance
Wed, 07 Feb 2024
Vaccinex Announces Pricing of $3.7 Million PIPE Financing - Stock Titan
Mon, 14 Sep 2020
VCNX - Vaccinex Inc Latest Stock News & Market Updates - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
OTC
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 1.18e+006 (%) |
| Held by Institutions | 11.5 (%) |
| Shares Short | 128 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.864e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 590.1 % |
| Return on Equity (ttm) | -376.1 % |
| Qtrly Rev. Growth | 601000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.47407e+007 |
| Qtrly Earnings Growth | -8.9 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -16 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.37 |
| Dividend | 0 |
| Forward Dividend | 62110 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|